China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking a commercial launch just six days after approval. The drug, conditionally approved in China on June 29th, is a self-discovered bispecific antibody (BsAb) indicated for the treatment of recurrent or metastatic cervical cancer that has failed previous platinum-based chemotherapy.
Drug Profile
Cadonilimab is an innovative bispecific antibody targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Akeso is further developing the drug for a range of indications, including liver, cervical, lung, and stomach cancers, as well as esophageal squamous cell carcinoma and nasopharyngeal carcinoma. The drug is expected to offer significantly lower toxicity and improved safety and efficacy compared to a combination of separate PD-1 and CTLA-4 antibodies.-Fineline Info & Tech
